The uncertainty among experts regarding the potential correlation between DFS and OS may in part be due to the lack of evidence demonstrating translation of DFS improvement into OS benefit with targeted therapies such as gefitinib and erlotinib in the adjuvant setting for EGFR-mutant NSCLC [26–28]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.